{"id": "patient_01_q0", "generated_text": "D: Vincristine is not part of the current treatment regimen for Mrs. Sample's DLBCL. The text lists the current treatment as \"R-Pola-CHP regimen q21\", which includes Polatuzumab ved", "model_name": "Qwen/Qwen2.5-7B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 0}}
{"id": "patient_01_q1", "generated_text": "D: She has 3-vessel CHD.\nThe information provided in the context states that Mrs. Sample has \"2-vessel CHD\" (coronary heart disease involving two of the three major coronary arteries), not 3-vessel", "model_name": "Qwen/Qwen2.5-7B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 0}}
{"id": "patient_01_q2", "generated_text": "A: Primary progressive type of multiple sclerosis (ID 03/02)\nBased on the provided context, Mrs. Sample suffers from a primary progressive type of multiple sclerosis (ID 03/02). Therefore, the correct option is", "model_name": "Qwen/Qwen2.5-7B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 0}}
{"id": "patient_01_q3", "generated_text": "B: Fingolimod 0.5mg, 1 capsule at bedtime, Note: Take a break as directed\nAnswer: B: Fingolimod 0.5mg, 1 capsule at bedtime, Note:", "model_name": "Qwen/Qwen2.5-7B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 0}}
{"id": "patient_01_q4", "generated_text": "D: 6 cycles of R-Pola-CHP\nAnswer:  D: 6 cycles of R-Pola-CHP\n\nBased on the context provided, the oncology board decision is clearly stated in the document: \"Onc", "model_name": "Qwen/Qwen2.5-7B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 0}}
{"id": "patient_01_q5", "generated_text": "C: Thoracic vertebra 10\nBased on the context provided, the metastasis that was surgically addressed is located at the thoracic vertebra 10. The relevant text from the initial update is as follows:\n\n**Pathology", "model_name": "Qwen/Qwen2.5-7B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 0}}
{"id": "patient_01_q6", "generated_text": "A: After uneventful intravenous administration of Omnipaque 320, a multi-slice helical CT of the chest, abdomen, and pelvis was performed during the venous phase of contrast enhancement.\n\n---\n\nContext for the next", "model_name": "Qwen/Qwen2.5-7B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 0}}
{"id": "patient_01_q7", "generated_text": "B: MR Spine plain + post-contrast from 12/20/2016, MR Head 3D unenhanced + contrast from 12/19/2016, CT Thoracic Sp", "model_name": "Qwen/Qwen2.5-7B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 0}}
{"id": "patient_01_q8", "generated_text": "**B: The patient started taking Pregabalin 75 mg, 1-0-1-0**.\n\nAnswer: **B: The patient started taking Pregabalin 75 mg, 1-0-1", "model_name": "Qwen/Qwen2.5-7B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 0}}
{"id": "patient_01_q9", "generated_text": "B: The patient's pain management was escalated, as indicated by an increased frequency of Hydromorphone intake. The text for this option is: \"Hydromorphone hydrochloride (extended-release) 2mg: Take", "model_name": "Qwen/Qwen2.5-7B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 0}}
